EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomimetic dexamethasone-loaded nanoparticles attenuate sepsis-induced acute lung injury

LiuGuang Song, ZheChu Xuan, ChunNa Jin, LiangLiang Jia, Nan Zheng, YuMeng Liu, ZhengMing Wu, Jian Shen, Huijun Liang

Frontiers in Pharmacology · 29.07.2026 · 17

DOI: 10.3389/fphar.2026.1857409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.07.2026. Verfasst von LiuGuang Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sepsis-induced acute lung injury (ALI) is a severe complication characterized by uncontrolled inflammation and high mortality, yet effective targeted therapies remain limited. Notably, acute myocardial infarction (MI) frequently coexists with or exacerbates ALI through shared inflammatory pathways. Dexamethasone (Dex) exerts potent anti-inflammatory effects but its clinical application is limited by non-specific biodistribution and dose-dependent off-target toxicities.

Methods

We developed a biomimetic nanoplatform Dex@mPLGA by coating dexamethasone-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles with RAW264.7 macrophage membranes. The physicochemical properties of Dex@mPLGA were systematically characterized. Cellular uptake, cytotoxicity, anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory effects were evaluated in LPS-stimulated RAW264.7 cells. In vivo biodistribution, therapeutic efficacy, and biosafety were further evaluated in an LPS-induced ALI mouse model.

Results

Dex@mPLGA exhibited a core–shell structure with an average particle size of 147.3 nm, negative surface charge, 3.2% drug loading, 74.6% encapsulation efficiency, good colloidal stability, and sustained Dex release. SDS-PAGE analysis supported the retention of macrophage membrane protein components in the final formulation. Dex@mPLGA was internalized by RAW264.7 macrophages in a time-dependent manner and showed minimal cytotoxicity at the tested concentrations. In LPS-stimulated macrophages, Dex@mPLGA alleviated inflammatory and oxidative stress-related responses relative to the LPS model, including improved cell viability, reduced ROS and MDA levels, decreased pro-inflammatory cytokine and NO production, increased IL-10 secretion, reduced apoptosis, restored proliferative activity, and modulation of macrophage polarization. Direct comparison with uncoated Dex@PLGA showed that the additional in vitro benefit of macrophage membrane coating was endpoint-dependent rather than universal. Statistically significant coating-associated improvements were mainly observed in cell viability, IL-10 secretion, EdU-positive proliferative recovery, and M2 polarization, whereas several inflammatory, oxidative stress-related, apoptotic, and M1-polarization readouts were comparable between Dex@PLGA and Dex@mPLGA. In vivo , Dex@mPLGA showed improved pulmonary accumulation in inflamed lung tissues, improved survival outcomes, reduced systemic pro-inflammatory cytokine levels, and alleviated lung histopathological injury. Short-term biosafety evaluation showed no obvious organ toxicity or abnormal serum biochemical changes under the tested conditions.

Conclusion

Dex@mPLGA represents an innovative biomimetic Dex delivery platform with therapeutic potential for sepsis-induced ALI. Its efficacy is likely associated with PLGA-mediated sustained Dex delivery, macrophage-associated uptake, selected membrane-related immunoregulatory benefits, and improved pulmonary accumulation in vivo . However, the incremental in vitro advantage of Dex@mPLGA over Dex@PLGA was modest and endpoint-dependent, and the membrane coating should be interpreted as providing selected auxiliary benefits rather than uniformly enhancing all biological outcomes. Further studies are needed to validate membrane-specific targeting and long-term safety in more physiologically relevant models.

Schlagwörter

Stichwörter der Autor:innen

PLGA nanoparticlesacute lung injurybiomimetic nanocarriersdexamethasoneinflammationsepsis

Autor:innen und Institutionen

  • Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.
  • Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, China.
  • School of Medicine and Nursing, Huzhou University, Huzhou, China.
  • Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
  • The Third People's Hospital of Deqing, Deqing Hospital of Hangzhou Normal University, Deqing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Song, L., Xuan, Z., Jin, C., Jia, L., Zheng, N., Liu, Y., Wu, Z., Shen, J., & Liang, H. (2026). Biomimetic dexamethasone-loaded nanoparticles attenuate sepsis-induced acute lung injury. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1857409

Vancouver

Song L, Xuan Z, Jin C, Jia L, Zheng N, Liu Y, et al. Biomimetic dexamethasone-loaded nanoparticles attenuate sepsis-induced acute lung injury. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1857409

BibTeX
@article{Song2026,
  author = {Song, LiuGuang and Xuan, ZheChu and Jin, ChunNa and Jia, LiangLiang and Zheng, Nan and Liu, YuMeng and Wu, ZhengMing and Shen, Jian and Liang, Huijun},
  title = {Biomimetic dexamethasone-loaded nanoparticles attenuate sepsis-induced acute lung injury},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1857409}
}
Kostenlos starten →